Log in
Enquire now
‌

US Patent 11254747 Covalent diabodies and uses thereof

Patent 11254747 was granted and assigned to MacroGenics on February, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
MacroGenics
MacroGenics
Date Filed
March 5, 2018
Date of Patent
February 22, 2022
Patent Applicant
MacroGenics
MacroGenics
Patent Application Number
15911869
Patent Citations
‌
US Patent 10131713 HER2/neu-specific antibodies and methods of using same
‌
US Patent 10150812 CD3-binding molecules capable of binding to human and non-human CD3
‌
US Patent 10160806 Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
‌
US Patent 10280231 Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
‌
US Patent 10344092 Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
‌
US Patent 10479831 BCR-complex-specific antibodies and methods of using same
‌
US Patent 10501552 Multivalent molecules comprising DR5-binding domains
‌
US Patent 10577422 PD-1-binding molecules and methods of use thereof
‌
US Patent 10633440 Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
‌
US Patent 10633443 Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11254747
Patent Primary Examiner
‌
Brad Duffy

Find more entities like US Patent 11254747 Covalent diabodies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.